Wells Fargo Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $26
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $43
Arcus Biosciences (NYSE:RCUS) Beats Q2 Estimates and Advances Casdatifan Pipeline
Arcus Biosciences, Inc. (RCUS) Q2 2026 Earnings Call Transcript
Arcus Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
Arcus Biosciences Q2 EPS $(0.72) Beats $(0.87) Estimate, Sales $41.000M Beat $23.405M Estimate
Arcus Biosciences Announces A Clinical Supply Agreement With AVEO Oncology To Evaluate Casdatifan; Agreement Supports A New Randomized Cohort Within The ARC-20 Study Evaluating Investigational Casdatifan Plus Tivozanib Versus Tivozanib Alone In Patients Who Received Prior HIF-2α-inhibitor Therapy; Enrollment Expected To Begin In Q4 2026
HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45
Arcus Biosciences Announces Publication In Nature Describing New Research From The ARC-20 Study Showing Casdatifan HIF-2a Inhibition Deeply Suppresses Serum EPO And Extends Progression-Free Survival In Advanced Kidney Cancer
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Slideshow
LifeSci Capital Initiates Coverage of Arcus Biosciences (RCUS) with Outperform Recommendation
Truist Securities Assumes Arcus Biosciences at Buy, Raises Price Target to $35
Newsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue Forecasts
Morgan Stanley Maintains Equal-Weight on Arcus Biosciences, Raises Price Target to $22
Analyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter Report
Goldman Sachs Maintains Buy on Arcus Biosciences, Raises Price Target to $34
Arcus Biosciences, Inc. 2026 Q1 - Results - Earnings Call Presentation
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
Arcus (RCUS) Q1 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.